Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 361

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 361
---
         | 2.30 |     |          |  6,179 |     |             |  8,407 |
| Series B    |     |                         | 5/3/2022   |     |            |    301 |     |             |    301 |     | $         | 3.00 |     |          |    580 |     |             |    903 |
| Series C    |     |                         | 8/29/2023  |     |            | 75,000 |     |             | 47,154 |     | $         | 1.50 |     |          | 68,773 |     |             | 70,731 |
|             |     |                         |            |     |            | 79,251 |     |             | 51,405 |     |           |      |     | $        | 75,967 |     | $           | 80,484 |

In August 2023, the Company closed the Series C Offering with four new investor groups (“Series C New Investors”) to invest $75.0 million of which $35.0 million was payable upon the first closing in August 2023 and $40.0 million payable upon the enrollment of the first patient into the Phase 2 trial of LB-102.The second closing occurred in January 2024. The Company issued 23.3 million and 26.7 million shares of Series C preferred stock at the first and second closings, respectively. In conjunction with the Series C Offering, the strike price of warrants held by Series A and Series B preferred stockholders was reduced to $0.01 per share and the Series B preferred stockholders received 100,373 newly issued warrants at a strike price of $1.50 (“New Series B Warrants”), allowing the Series B preferred stockholders to purchase common stock in an amount equal to one-thirdof their current Series B preferred stock. See Warrants section below for additional information. The Company incurred issuance costs of $2.0 million associated with the Series C preferred stock and New Series B Warrants. Upon the closing of the Series C Offering, the 2020 Notes and 2022 Notes automatically converted to 23.8 million shares of Series C preferred stock at a price of $1.50 per share. See Note 11 Notesfor additional information. As of December 31, 2024, the holders of the Preferred Stock have the following